Delyse Garg, MD
Pulmonary Disease · Marshfield, WINPI 1811340813
Payments from drug & device makers
Across 53 payments — averaging $47.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Noah Medical Corporation$1K
- AstraZeneca$276
- GSK$201
- Boehringer Ingelheim$144
- Johnson & Johnson$125
- Actelion Pharmaceuticals US, Inc.$122
- plus $406 from 10 others
What the payments were for
- Travel & lodging$88735%
- Food & beverage$1,63365%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Noah Medical Corporation | 9 | $1,246 |
| AstraZeneca | 6 | $276 |
| GSK | 8 | $201 |
| Boehringer Ingelheim | 9 | $144 |
| Johnson & Johnson | 4 | $125 |
| Actelion Pharmaceuticals US, Inc. | 1 | $122 |
| Portola Pharmaceuticals, LLC | 1 | $119 |
| Gilead | 1 | $100 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $68 |
| Shire North American Group Inc | 3 | $42 |
| Covidien LP | 1 | $17 |
| Pfizer | 1 | $15 |
| Amgen | 1 | $14 |
| CSL Behring | 1 | $14 |
| Akcea Therapeutics, Inc. | 1 | $13 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,521 in reported general payments places this provider in the 60th percentile of 247 pulmonary disease providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 120 | $64,519 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 79 | $54,045 |
| NucalaMepolizumab | 12 | $51,532 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 80 | $41,643 |
| Spiriva RespimatTiotropium Bromide | 59 | $32,326 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 118 | $17,100 |
| Advair HfaFluticasone Propion/Salmeterol | 35 | $13,783 |
| Spiriva HandihalerTiotropium Bromide | 21 | $11,088 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $8,773 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 18 | $8,368 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 231 | $6,734 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 33 | $5,777 |
| SymbicortBudesonide/Formoterol Fumarate | 19 | $4,118 |
| Fluticasone Propionate HfaFluticasone Propionate | 14 | $3,772 |
| Arnuity ElliptaFluticasone Furoate | 12 | $3,062 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta | $201 | $159,054202 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat, Combivent Respimat | $144 | $105,213197 claims |
| AstraZenecaSymbicort | $276 | $4,11819 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 247 pulmonary disease providers in Wisconsin.
Other pulmonary disease in Marshfield
- Andrew BraunMadison$1.6M
- Kenneth PresbergMilwaukee$1.4M
- Jonathan KurmanMilwaukee$1.1M
- Stephen HallidayMadison$898K
- Daniel LeonardAppleton$719K
- Hasnain BawaadamKenosha$714K
- Mouhammed RihawiMilwaukee$713K
- Mark BarashMilwaukee$498K
- Julie BillerMilwaukee$479K
- Paul LisiCudahy$423K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.